Relmada Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Relmada Therapeutics, Inc.'s free cash flow has increased -11.53% from $-51.76M last year to $-45.79M, signaling increasing performance

Relmada Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Relmada Therapeutics, Inc. has insufficient data to evaluate this check.

Relmada Therapeutics, Inc. has a net cash position, so leverage is healthy.

Relmada Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Relmada Therapeutics, Inc. has insufficient data to evaluate this check.

Relmada Therapeutics, Inc.'s short-term assets of $93.98M exceed its short-term liabilities of $6.43M

Relmada Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Relmada Therapeutics, Inc.'s return on equity of -47.52%, is lower than 15.00%, indicating bad performance

Relmada Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Relmada Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Relmada Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Relmada Therapeutics, Inc. has negative free cash flow, indicating cash burn

Relmada Therapeutics, Inc.'s yearly earnings has increased -28.25% since last year from $-79.98M to $-57.39M, signaling increasing performance

Relmada Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -30.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Relmada Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Relmada Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Relmada Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Relmada Therapeutics, Inc. has insufficient data to evaluate this check.

Relmada Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Relmada Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Relmada Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Relmada Therapeutics, Inc. has insufficient data to evaluate this check.

Relmada Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Relmada Therapeutics, Inc. has a price-to-book ratio of 2.47x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Relmada Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue